Modulation of Inflammation and Gut Microbiota by a Bifidobacterium longum Extracellular Vesicle-Based Drug Delivery System for Alleviating Inflammatory Bowel Disease
Pharmaceutics · 30.04.2026 · 18 (5) · 553
DOI: 10.3390/pharmaceutics18050553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.04.2026. Verfasst von Chunlei Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Binzhou Medical University, 346# Guanhai Road, Yantai 264003, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Taishan Scholar Foundation of Shandong Province, Yantai Natural Science Foundation Project.
Abstract (Originalsprache)
Purpose
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder strongly associated with intestinal microbial dysregulation. Although 5-aminosalicylic acid (5-ASA) is widely used in the clinical management of IBD, its therapeutic efficacy is often limited. To address this, the present study aimed to develop a bifidobacterium-derived extracellular vesicle-based drug delivery system (B-MVs@5-ASA) to enhance the therapeutic outcomes of IBD.
Methods
B-MVs were isolated by PEG precipitation and loaded with 5-ASA via sonication to obtain B-MVs@5-ASA. Their morphology, particle size, zeta potential, and encapsulation efficiency were analyzed using TEM, DLS, and UV spectrophotometry. Cellular uptake, cytotoxicity (LDH and NO assays), and anti-inflammatory effects were assessed in RAW 264.7 and Caco-2 cells. A DSS-induced colitis mouse model was established to evaluate therapeutic efficacy. Cytokines (ELISA), colon histopathology (H&E), tight-junction proteins (IF), and gut microbiota composition (16S rRNA sequencing) were systematically analyzed.
Results
B-MVs@5-ASA exhibited a particle size of 104.3 ± 2.81 nm and an encapsulation efficiency of 11.14% ± 3.63%. B-MVs@5-ASA exhibited the strongest anti-inflammatory effect in vitro and most effectively alleviated DSS-induced colitis in vivo, outperforming monotherapies in reducing inflammation, tissue damage, and enhancing barrier integrity. B-MVs@5-ASA further promoted goblet cell regeneration and beneficially modulated the gut microbiota by enriching Akkermansia and suppressing Escherichia, thereby restoring microbial homeostasis.
Conclusions
B-MVs@5-ASA provides potent anti-inflammatory and mucosal-protective effects by modulating cytokine balance, enhancing epithelial barrier function, and reshaping gut microbiota. These findings highlight probiotic vesicle-based nanoplatforms as a safe and promising strategy for targeted IBD therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Binzhou Medical University, 346# Guanhai Road, Yantai 264003, China.
- Department of Microbiology, College of Life Sciences, Shandong Agricultural University, Taian 271018, China.
ORCID-Profile: Ying Zhang
Förderung
- National Natural Science Foundation of China
- Taishan Scholar Foundation of Shandong Province
- Yantai Natural Science Foundation Project
- Taishan Scholar Foundation of Shandong Province, China
- leading talents at the provincial level in Yantai city, China
- Yantai Natural Science Foundation Project, China
Zitieren
APA
Ma, C., Shi, S., Wang, W., Li, B., Li, Z., Cui, Y., Li, F., Chen, X., & Zhang, Y. (2026). Modulation of Inflammation and Gut Microbiota by a Bifidobacterium longum Extracellular Vesicle-Based Drug Delivery System for Alleviating Inflammatory Bowel Disease. Pharmaceutics, 18(5), 553. https://doi.org/10.3390/pharmaceutics18050553
Vancouver
Ma C, Shi S, Wang W, Li B, Li Z, Cui Y, et al. Modulation of Inflammation and Gut Microbiota by a Bifidobacterium longum Extracellular Vesicle-Based Drug Delivery System for Alleviating Inflammatory Bowel Disease. Pharmaceutics. 2026;18(5):553. doi:10.3390/pharmaceutics18050553
BibTeX
@article{Ma2026,
author = {Ma, Chunlei and Shi, Shang and Wang, Wenke and Li, Boqing and Li, Zhiqin and Cui, Yingzi and Li, Fangshu and Chen, Xiaoying and Zhang, Ying},
title = {Modulation of Inflammation and Gut Microbiota by a Bifidobacterium longum Extracellular Vesicle-Based Drug Delivery System for Alleviating Inflammatory Bowel Disease},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {5},
pages = {553},
doi = {10.3390/pharmaceutics18050553}
}
EUVIMED